What question did this study set out to answer?

The research aims to identify novel therapeutic candidates for moderate to severe ulcerative colitis (UC) using bioinformatics and in vitro methods.

April 11, 2026

Integrated bioinformatics analysis and in vitro validation reveal Dasatinib and Acetalax as novel therapeutic candidates for treating moderate to severe forms of ulcerative colitis

Puntos clave

The research aims to identify novel therapeutic candidates for moderate to severe ulcerative colitis (UC) using bioinformatics and in vitro methods.
Conducted integrative bioinformatics analysis on transcriptomic alterations related to UC
Identified and validated dysregulated genes in moderate-to-severe UC
Predicted drug candidates through molecular docking and drug prediction frameworks
Performed in vitro validation using LPS-stimulated Caco-2 cells for drug effects
Identified thirty persistently dysregulated genes correlated with immune components like neutrophils
Dasatinib and Acetalax emerged as promising therapeutic candidates after drug prediction
Both drugs enhanced cell viability and affected inflammation-related gene and protein expressions

Resumen

We analyzed transcriptomic alterations, immune infiltration, and candidate drugs in moderate-to-severe ulcerative colitis (UC) using integrative bioinformatics and in vitro validation. Thirty persistently dysregulated genes were identified and externally validated, with neutrophils emerging as a key immune component correlated with HSD11B2, SPP1, and FAM55A. Drug prediction and molecular docking highlighted Dasatinib and Acetalax as candidate compounds. In LPS-stimulated Caco-2 cells, both drugs improved viability and modulated inflammation-related gene and protein expression. These findings provide hypothesis-generating evidence that Dasatinib and Acetalax may have therapeutic relevance in moderate-to-severe UC.

Me gusta

Guardar